

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KELUN-BIOTECH
科伦博泰

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

TRADING HALT

At the request of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”), trading in the H shares of the Company on the main board of The Stock Exchange of Hong Kong Limited has been halted with effect from 1:00 p.m. on Friday, October 20, 2023, pending the release of announcement(s) in relation to potential inside information of the Company.

By order of the Board

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

LIU Gexin

Chairman of the Board and Non-executive Director

Hong Kong, October 20, 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou and Dr. WANG Jingyi as executive Directors, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping, and Dr. LI Yuedong as independent non-executive Directors.